MedicaidPrior AuthMedium impact
Folotyn® (pralatrexate) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Indiana Medicaid has introduced a new prior authorization policy for Folotyn (pralatrexate), a chemotherapy drug used to treat relapsed or refractory peripheral T-cell lymphoma. Prior authorization is required for both brand and generic pralatrexate intravenous solutions effective January 1, 2026.
Action Required
By January 1, 2026: Billing team must update prior authorization requirements for Folotyn (pralatrexate) intravenous solutions for Humana Indiana Medicaid patients. Visit www.humana.com/PAL to obtain specific medical and procedural coding information. Ensure providers document that the drug is being used for relapsed or refractory peripheral T-cell lymphoma and that patients are receiving required vitamin supplementation. Claims without prior authorization will be denied.